PetVivo Holdings IncChange company Symbol lookupSelect an option...PETV PetVivo Holdings IncTFPM Triple Flag Precious Metals CorpSCLXW Scilex Holding Equity Warrants Exp 11th Oct 2027 *W EXP 10/11/2027GMBL Esports Entertainment Group IncCFRX ContraFect CorpAAL American Airlines Group IncNVDA NVIDIA CorpAMD Advanced Micro Devices IncQQQ Invesco QQQ TrustAAPL Apple IncGo
PetVivo Holdings, Inc. is a development-stage company. The Company is a biomedical device company focused on licensing and commercialization of medical devices and therapeutics for pets. The Company's operating subsidiary, PetVivo, Inc., (PetVivo) is engaged in the business of acquiring/in-licensing and adapting human biomedical technology and products for commercial sale in the veterinary market to treat pets and other animals suffering from arthritis and other painful affliction. As of March 31, 2015, PetVivo's pipeline included 17 therapeutic devices for both veterinary and human clinical applications. PetVivo's pipeline includes VD-01, VD-02 and VD-06, which are indicated for osteoarthritis, and VD-04, which is indicated for urinary incontinence, among others. Its subsidiary also includes Gel-Del Technologies, Inc., which has completed a pivotal clinical trial using their thermoplastic biomaterial as a dermal filler for human cosmetic applications.
|
|
|
|
| |
Company Profile
PetVivo Holdings, Inc. is a development-stage company. The Company is a biomedical device company focused on licensing and commercialization of medical devices and therapeutics for pets. The Company's operating subsidiary, PetVivo, Inc., (PetVivo) is engaged in the business of acquiring/in-licensing and adapting human biomedical technology and products for commercial sale in the veterinary market to treat pets and other animals suffering from arthritis and other painful affliction. As of March 31, 2015, PetVivo's pipeline included 17 therapeutic devices for both veterinary and human clinical applications. PetVivo's pipeline includes VD-01, VD-02 and VD-06, which are indicated for osteoarthritis, and VD-04, which is indicated for urinary incontinence, among others. Its subsidiary also includes Gel-Del Technologies, Inc., which has completed a pivotal clinical trial using their thermoplastic biomaterial as a dermal filler for human cosmetic applications.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- 67.12x
- Price/Book (MRQ)
- 9.22x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Gregory D. Cash
- John LaiPres.
- Robert J. FolkesCFO
- Randall A. MeyerCOO
- John Fitzgerald Dolan
Address
- 5251 Edina Industrial Blvd
- Edina, MN 55439
- Phone: (952) 217-4952
- Fax: (775) 884-9383
- https://petvivo.com/
Insider Trading
During the most recent quarter, 22K shares were bought in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.